Circulating Pentraxin-3 and its association with C-reactive protein levels and disease activity in patients with chronic spontaneous urticaria
Main Article Content
Keywords
C-reactive protein, chronic spontaneous urticaria, D-dimer, pentraxin-3, urticaria activity score
Abstract
Introduction: Pentraxin-3 (PTX3) is a soluble long pentraxin molecule that regulates inflammatory responses. This study aimed to determine the plasma levels of plasma PTX-3 as an inflammation marker in chronic spontaneous urticaria (CSU) and whether the PTX3 levels correlate with disease activity and other clinical parameters, including acute phase reactants and biomarkers.
Methods: The study included 70 CSU patients and 30 healthy controls. Plasma PTX3 levels were measured by ELISA. CSU disease activity was evaluated with the urticaria activity score summed over 7 days. Complete blood count, C-reactive protein (CRP), transaminases, total IgE, antinuclear antibody, anti-thyroid peroxidase, anti-thyroglobulin, and D-dimer levels were recorded.
Results: Of the 70 patients, 52 (74.3%) were female, with a mean age of 37.51 ± 11.80 years. Disease activity was severe in 43, moderate in 15, and mild in 12 patients. Mean PTX3 levels were elevated in CSU patients compared to healthy controls (0.81 vs. 0.55 ng/mL, p = 0.031). The mean CRP levels were higher in patients than in the controls (4.26 vs. 1.57 mg/L, p = 0.023). Patients also had higher D-dimer levels than the controls (5.96 vs. 0.59 mg/L, p < 0.001). A significant positive correlation was found between PTX3 and CRP levels (r = 0.508, p < 0.001) and between D-dimer levels and UAS7 (r = 0.338, p = 0.004) and CRP (r = 0.213, p = 0.034) levels. A multivariable stepwise regression analysis showed that the one-unit increase in the CRP level increased to 38.19 units in the PTX3 level (95% confidence interval [17.40–58.98], p < 0.001).
Conclusion: Circulating levels of CRP and PTX3, two members of the pentraxin family, are significantly correlated and elevated in CSU patients with increasing disease activity, indicating their utility as inflammatory markers in CSU.
References
2. Sanchez-Borges M, Ansotegui IJ, Baiardini I, Bernstein J, Canonica GW, Ebisawa M, et al. The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management. World Allergy Organ J. 2021;14(6):100533. 10.1016/j.waojou.2021.100533
3. Folci M, Ramponi G, Brunetta E. A Comprehensive Approach to Urticaria: From Clinical Presentation to Modern Biological Treatments Through Pathogenesis. Adv Exp Med Biol. 2021;1326:111–37. 10.1007/5584_2020_612
4. Asero R, Tedeschi A, Marzano AV, Cugno M. Chronic urticaria: a focus on pathogenesis. F1000Res. 2017;6:1095. 10.12688/f1000research.11546.1
5. Zhou B, Li J, Liu R, Zhu L, Peng C. The Role of Crosstalk of Immune Cells in Pathogenesis of Chronic Spontaneous Urticaria. Front Immunol. 2022;13:879754. 10.3389/fimmu.2022.879754
6. Puxeddu I, Petrelli F, Angelotti F, Croia C, Migliorini P. Biomarkers In Chronic Spontaneous Urticaria: Current Targets And Clinical Implications. J Asthma Allergy. 2019;12:285–95. 10.2147/JAA.S184986
7. Grzanka R, Damasiewicz-Bodzek A, Kasperska-Zajac A. Interplay between acute phase response and coagulation/fibrinolysis in chronic spontaneous urticaria. Allergy Asthma Clin Immunol. 2018;14:27. 10.1186/s13223-018-0255-8
8. Folci M, Heffler E, Canonica GW, Furlan R, Brunetta E. Cutting Edge: Biomarkers for Chronic Spontaneous Urticaria. J Immunol Res. 2018;2018:5615109. 10.1155/2018/5615109
9. Maurer M, Eyerich K, Eyerich S, Ferrer M, Gutermuth J, Hartmann K, et al. Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. Int Arch Allergy Immunol. 2020;181(5):321–33. 10.1159/000507218
10. Bottazzi B, Inforzato A, Messa M, Barbagallo M, Magrini E, Garlanda C, et al. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J Hepatol. 2016;64(6):1416–27. 10.1016/j.jhep.2016.02.029
11. Daigo K, Mantovani A, Bottazzi B. The yin-yang of long pentraxin PTX3 in inflammation and immunity. Immunol Lett. 2014;161(1):38–43. 10.1016/j.imlet.2014.04.012
12. Kolkhir P, Altrichter S, Hawro T, Maurer M. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria. Allergy. 2018;73(4):940–8. 10.1111/all.13352
13. Kasperska-Zajac A, Sztylc J, Machura E, Jop G. Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients. Clin Exp Allergy. 2011;41(10):1386–91. 10.1111/j.1365-2222.2011.03789.x
14. Moalli F, Jaillon S, Inforzato A, Sironi M, Bottazzi B, Mantovani A, et al. Pathogen recognition by the long-pentraxin PTX3. J Biomed Biotechnol. 2011;2011:830421. 10.1155/2011/830421
15. Cieslik P, Hrycek A. Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action, and clinical implications. Autoimmunity. 2012;45(2):119–28. 10.3109/08916934.2011.611549
16. Wang Z, Wang X, Zou H, Dai Z, Feng S, Zhang M, et al. The Basic Characteristics of the Pentraxin Family and Their Functions in Tumor Progression. Front Immunol. 2020;11:1757. 10.3389/fimmu.2020.01757
17. Jaillon S, Bonavita E, Gentile S, Rubino M, Laface I, Garlanda C, et al. The long pentraxin PTX3 as a key component of humoral innate immunity and a candidate diagnostic for inflammatory diseases. Int Arch Allergy Immunol. 2014;165(3):165–78. 10.1159/000368778
18. Zhang H, Wang R, Wang Z, Wu W, Zhang N, Zhang L, et al. Molecular insight into pentraxin-3: Update advances in innate immunity, inflammation, tissue remodeling, diseases, and drug role. Biomed Pharmacother. 2022;156:113783. 10.1016/j.biopha.2022.113783
19. Du JY, Lai HY, Hsiao YW, Chi JY, Wang JM. Pentraxin 3 Facilitates Shrimp-Allergic Responses in IgE-Activated Mast Cells. J Immunol Res. 2022;2022:8953235. 10.1155/2022/8953235
20. Kasperska-Zajac A, Grzanka A, Misiolek M, Mazur B, Machura E. Pentraxin-3 as a local inflammatory marker in chronic spontaneous urticaria. Cytokine. 2015;76(2):566–8. 10.1016/j.cyto.2015.04.016
21. Balhara J, Shan L, Zhang J, Muhuri A, Halayko AJ, Almiski MS, et al. Pentraxin 3 deletion aggravates allergic inflammation through a T(H)17-dominant phenotype and enhanced CD4 T-cell survival. J Allergy Clin Immunol. 2017;139(3):950–63.e9. 10.1016/j.jaci.2016.04.063
22. Atwa MA, Emara AS, Youssef N, Bayoumy NM. Serum concentration of IL-17, IL-23, and TNF-alpha among patients with chronic spontaneous urticaria: association with disease activity and autologous serum skin test. J Eur Acad Dermatol Venereol. 2014;28(4):469–74. 10.1111/jdv.12124
23. Prosty C, Gabrielli S, Ben-Shoshan M, Le M, Gimenez-Arnau AM, Litvinov IV, et al. In silico Identification of Immune Cell-Types and Pathways Involved in Chronic Spontaneous Urticaria. Front Med (Lausanne). 2022;9:926753. 10.3389/fmed.2022.926753
24. Gao P, Tang K, Wang M, Yang Q, Xu Y, Wang J, et al. Pentraxin levels in non-eosinophilic versus eosinophilic asthma. Clin Exp Allergy. 2018;48(8):981–9. 10.1111/cea.13168
25. Licari A, Marseglia G, De Amici M, Ciprandi G. Pentraxin 3 and D-dimer in children with asthma: A real-world study. Clin Exp Allergy. 2019;49(4):550–1. 10.1111/cea.13364
26. Grzanka A, Damasiewicz-Bodzek A, Kasperska-Zajac A. The relationship between circulating concentrations of interleukin 17 and C reactive protein in chronic spontaneous urticaria. Allergy Asthma Clin Immunol. 2017;13:25. 10.1186/s13223-017-0197-6
27. Plavsic A, Tomic-Spiric V, Arandjelovic S, Miskovic R, Dimitrijevic M, Peric-Popadic A. Biomarkers of disease activity in patients with chronic spontaneous urticaria. Postepy Dermatol Alergol. 2021;38(6):1017–22. 10.5114/ada.2021.112276
28. Ohtsuka T. Response to oral cyclosporine therapy and high sensitivity-CRP level in chronic idiopathic urticaria. Int J Dermatol. 2010;49(5):579–84. 10.1111/j.1365-4632.2010.04384.x
29. Kolkhir P, Pogorelov D, Olisova O. CRP, D-dimer, fibrinogen and ESR as predictive markers of response to standard doses of levocetirizine in patients with chronic spontaneous urticaria. Eur Ann Allergy Clin Immunol. 2017;49(4):189–92. 10.23822/EurAnnACI.1764-1489.05
30. de Montjoye L, Darrigade AS, Gimenez-Arnau A, Herman A, Dumoutier L, Baeck M. Correlations between disease activity, autoimmunity, and biological parameters in patients with chronic spontaneous urticaria. Eur Ann Allergy Clin Immunol. 2021;53(2):55–66. 10.23822/EurAnnACI.1764-1489.132
31. Kasperska-Zajac A, Grzanka A, Jarzab J, Misiolek M, Wyszynska-Chlap M, Kasperski J, et al. The association between platelet count and acute phase response in chronic spontaneous urticaria. Biomed Res Int. 2014;2014:650913. 10.1155/2014/650913
32. Asero R, Tedeschi A, Riboldi P, Griffini S, Bonanni E, Cugno M. Severe chronic urticaria is associated with elevated plasma levels of D-dimer. Allergy. 2008;63(2):176–80.
33. Cugno M, Marzano AV, Asero R, Tedeschi A. Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications. Intern Emerg Med. 2010;5(2):97–101. 10.1007/s11739-009-0333-5
34. Farres MN, Refaat M, Melek NA, Ahmed EE, Shamseldine MG, Arafa NA. Activation of coagulation in chronic urticaria in relation to disease severity and activity. Allergol Immunopathol (Madr). 2015;43(2):162–7. 10.1016/j.aller.2014.04.002
35. Gimenez-Arnau AM, DeMontojoye L, Asero R, Cugno M, Kulthanan K, Yanase Y, et al. The Pathogenesis of Chronic Spontaneous Urticaria: The Role of Infiltrating Cells. J Allergy Clin Immunol Pract. 2021;9(6):2195–208. 10.1016/j.jaip.2021.03.033
36. Relvas M, Silva J, Matos AL, Alves F, Goncalo M. Concomitant evaluation of d-dimer and C-reactive protein in chronic spontaneous urticaria may show divergent values. Eur Ann Allergy Clin Immunol. 2022. 10.23822/EurAnnACI.1764-1489.259
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.